All News

Senate hearing reveals tensions between scientific consensus and HHS Secretary Kennedy's claims on Alzheimer research funding and priorities.

The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.

Your daily dose of the clinical news you may have missed.

Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.

HHS Secretary Kennedy announced the CDC will no longer recommend vaccination against infection with SARS-CoV-2 for the 2 vulnerable populations.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.

Telemedicine's trajectory depends far more on future regulatory action than on health care's readiness or patient desire, according to a new report.

Your daily dose of the clinical news you may have missed.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Your daily dose of the clinical news you may have missed.

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.

Results showed that a nanoencapsulated CBD cream reduced UV-A–induced nuclear and mitochondrial DNA damage linked to photoaging in human skin.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.